Concord Biotech Reports Strong Financial Results, Indicating Positive Growth Trajectory

May 30 2025 09:16 AM IST
share
Share Via
Concord Biotech has announced its financial results for the quarter ending March 2025, showcasing significant growth in net sales, profit before tax, and profit after tax. The company achieved its highest operating profit margin and earnings per share in five quarters, indicating improved efficiency and strong performance.
Concord Biotech, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results, declared on May 29, 2025, indicate a notable shift in the company's evaluation, with a revision in its score reflecting the positive financial performance observed during this period.

The company achieved net sales of Rs 429.88 crore, marking a significant growth compared to the average net sales of the previous four quarters, which stood at Rs 272.29 crore. This quarter's sales represent the highest figure recorded in the last five quarters, suggesting a robust near-term sales trend.

Profit Before Tax less Other Income (PBT) also saw a substantial increase, reaching Rs 174.16 crore, again the highest in the last five quarters. Similarly, Profit After Tax (PAT) was reported at Rs 140.39 crore, indicating a strong performance relative to the previous averages.

Additionally, Concord Biotech reported its highest operating profit margin at 44.30%, reflecting improved efficiency. The Earnings per Share (EPS) also reached a peak of Rs 13.42, showcasing the company's ability to generate higher earnings for its shareholders.

Overall, these financial results highlight a positive trajectory for Concord Biotech, leading to adjustments in its evaluation metrics.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News